Key Points
- CFO Kevin Feeley sold 317 shares on January 29 at an average price of $93.99 for $29,794.83, leaving him with 9,168 shares (a 3.34% reduction in his position).
- The January sale is part of a recent pattern of insider selling by Feeley, who also sold 3,855 shares on December 16 at $143.87 and 1,266 shares on December 9 at $159.28.
- GeneDx (NASDAQ:WGS) trades near $99 with a one-year range of $55.17–$170.87, a market cap around $2.86 billion, and an analyst consensus of "Moderate Buy" with an average price target of $138.13.
GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 317 shares of the business's stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $93.99, for a total value of $29,794.83. Following the transaction, the chief financial officer owned 9,168 shares in the company, valued at $861,700.32. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Kevin Feeley also recently made the following trade(s):
- On Tuesday, December 16th, Kevin Feeley sold 3,855 shares of GeneDx stock. The shares were sold at an average price of $143.87, for a total value of $554,618.85.
- On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total value of $201,648.48.
GeneDx Trading Up 2.9%
NASDAQ:WGS opened at $99.01 on Tuesday. GeneDx Holdings Corp. has a 1 year low of $55.17 and a 1 year high of $170.87. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71. The stock has a fifty day moving average price of $132.47 and a two-hundred day moving average price of $125.01. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 1,100.11 and a beta of 2.01.
Institutional Trading of GeneDx
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in WGS. Arizona State Retirement System lifted its holdings in GeneDx by 2.1% in the 4th quarter. Arizona State Retirement System now owns 5,594 shares of the company's stock valued at $728,000 after purchasing an additional 113 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of GeneDx by 5.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company's stock valued at $399,000 after buying an additional 181 shares during the period. Jones Financial Companies Lllp grew its stake in GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after acquiring an additional 186 shares during the period. Quarry LP raised its holdings in GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company's stock valued at $32,000 after acquiring an additional 209 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in shares of GeneDx by 9.2% during the 4th quarter. Pictet Asset Management Holding SA now owns 2,922 shares of the company's stock worth $380,000 after purchasing an additional 246 shares during the period. Hedge funds and other institutional investors own 61.72% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on WGS shares. Weiss Ratings reiterated a "sell (d)" rating on shares of GeneDx in a research report on Wednesday, January 21st. BTIG Research boosted their target price on GeneDx from $165.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. Wall Street Zen upgraded GeneDx from a "hold" rating to a "buy" rating in a research report on Saturday. Guggenheim reiterated a "buy" rating and issued a $170.00 price objective (up from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Finally, Wells Fargo & Company set a $155.00 target price on shares of GeneDx and gave the company an "equal weight" rating in a report on Monday, December 15th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $138.13.
Read Our Latest Analysis on WGS
GeneDx Company Profile
(
Get Free Report)
GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.
Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
